NSE · KRMAYURVED
KRM Ayurveda Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹77 Cr with net profit ₹12 Cr — a 15.72% net margin, versus 5.05% the period before.
Shareholding
As of 2026-03-31
- Promoter69.15%
- Public23.65%
- FII3.86%
- DII3.34%
536 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.74× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — ESM · ESM 1. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Healthcare · ranked #1 of 79 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Apollo Hospitals Enter. Limited | ₹1,28,472 Cr | 242.67 | 13.55 | 20.48% | 7.7% |
| Max Healthcare Institute Ltd. | ₹1,08,166 Cr | 315.74 | 10.06 | 13.42% | 17.23% |
| Fortis Healthcare Ltd. | ₹71,876 Cr | 270.47 | 7.26 | 10.53% | 11.41% |
| Narayana Hrudayalaya Ltd. | ₹42,315 Cr | 187.89 | 9.33 | 17.76% | 10.2% |
| Aster DM Healthcare Ltd. | ₹42,227 Cr | 299.63 | 9.23 | 8.48% | 8.36% |
| Global Health Limited | ₹38,526 Cr | 267.33 | 9.72 | 14.05% | 12.62% |
| Krishna Institute of Medical Sciences Ltd. | ₹31,931 Cr | 752.83 | 14.2 | 10.74% | 6.18% |
| Dr. Lal Path Labs Ltd. | ₹31,558 Cr | 239.5 | 12.58 | 20.13% | 18.27% |
| Poly Medicure Ltd. | ₹17,015 Cr | 256.67 | 5.48 | 10.37% | 17.18% |
| Dr. Agarwal's Health Care Limited | ₹15,494 Cr | 391.04 | 7.65 | 6.58% | 6.4% |
| KRM Ayurveda Limited(this company) | — | 0 | 4.55 | 17.54% | 0% |
AI analysis
AI-generated · google/gemini-2.5-flashKRM Ayurveda Limited, operating in the Healthcare sector, is currently under ESM Stage 1 surveillance. The company reported a 52-week high of Rs 271 and a 52-week low of Rs 156.15. As of March 31, 2026, promoter shareholding stands at 69.15%, with no shares pledged.
Positives
- +Return on capital employed (ROCE) is high at 41.34%.
- +Return on equity (ROE) is 17.54%.
- +Promoter pledge is 0% as of March 31, 2026.
Negatives
- −Revenue decreased by 24.39% from Mar 2023 to Mar 2024.
- −Net profit decreased by 55.07% from Mar 2023 to Mar 2024.
- −Profit margin is 0%.
- −Debt-to-equity ratio is high at 1.52.
- −Promoter shareholding decreased from 92.15% in Sep 2025 to 69.15% in Mar 2026.
Financial Performance
KRM Ayurveda Limited's revenue decreased by 24.39% from Rs 89.37 Cr in Mar 2023 to Rs 67.57 Cr in Mar 2024. Subsequently, revenue increased by 13.88% to Rs 76.94 Cr in Mar 2025. Net profit showed a similar trend, falling from Rs 7.59 Cr in Mar 2023 to Rs 3.41 Cr in Mar 2024, a decline of 55.07%, before rising to Rs 12.09 Cr in Mar 2025, an increase of 254.54%.
Profitability & Returns
The company's return on equity (ROE) is 17.54%, while its return on capital employed (ROCE) is 41.34%. KRM Ayurveda Limited has a profit margin of 0%. The earnings per share (EPS) was Rs 5.07 in Mar 2023, Rs 2.27 in Mar 2024, and Rs 8.06 in Mar 2025.
Balance Sheet
KRM Ayurveda Limited has a debt-to-equity ratio of 1.52. The book value per share is Rs 56.55. The company does not currently offer a dividend, with a dividend yield of 0%.
Ownership & Pledges
FII holding is 3.85% and DII holding is 3.33%. Public shareholding is 23.65%. There are no pledged promoter shares, with promoter pledge at 0%.
Regulatory & Surveillance
KRM Ayurveda Limited is under ESM Stage 1 surveillance. This indicates specific monitoring measures are in place for the company's shares.
Data as of — price: 2026-07-29 · financials: Mar 25 · shareholding: Mar 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.